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ABSTRACT: Human IgG Fc glycosylation modulates
immunological eﬀector functions such as antibody-dependent
cellular cytotoxicity and phagocytosis. Engineering of Fc
glycans therefore enables ﬁne-tuning of the therapeutic
properties of monoclonal antibodies. The N-linked glycans
of Fc are typically complex-type, forming a network of
noncovalent interactions along the protein surface of the Cγ2
domain. Here, we manipulate the mammalian glycan-
processing pathway to trap IgG1 Fc at sequential stages of maturation, from oligomannose- to hybrid- to complex-type
glycans, and show that the Fc is structurally stabilized following the transition of glycans from their hybrid- to complex-type state.
X-ray crystallographic analysis of this hybrid-type intermediate reveals that N-linked glycans undergo conformational changes
upon maturation, including a ﬂip within the trimannosyl core. Our crystal structure of this intermediate reveals a molecular basis
for antibody biogenesis and provides a template for the structure-guided engineering of the protein−glycan interface of
therapeutic antibodies.
■ INTRODUCTION
Antibodies are multifunctional glycoproteins, able to bind
antigens through variable Fab domains and cellular receptors
via the constant Fc region. This dual functionality enables the
recruitment of the cellular immune system to sites of infection
by antibody-dependent cellular cytotoxity (ADCC) and
antibody-dependent cellular phagocytosis (ADCP), and can
lead to the localized activation of the complement system.
Glycan and protein engineering of the Fc domain can generate
therapeutic monoclonal antibodies with tailored receptor
binding functionality.1,2 In contrast to chemical and chemo-
enzymatic methods to modulate glycan structures,3−9 we use
glycosidase inhibitors and a cell line deﬁcient in a
glycosyltransferase to generate antibody glycoforms containing
speciﬁc carbohydrate structures.
The Fc region of immunoglobulin G (IgG) is a homodimer
consisting primarily of heavy chain Cγ2 and Cγ3 domains. The
C-terminal Cγ3 domain protomers interact through an
extended protein−protein interface, occluding over 1100 Å2
of protein surface,10 and adopt rigid conformations that exhibit
little structural variation.11 In contrast, the Cγ2 domain
protomers have only been observed to interact via glycan−
glycan contacts between opposing N-linked chains at
Asn297.11−13 Glycan-mediated maintenance of the spacing
between the Cγ2 domains is critical for cellular Fcγ receptor
(FcγR) binding, which occurs asymmetrically at the tip of the
Cγ2 domains and lower hinge region.14 Deglycosylation, for
example, by bacterial endoglycosidases, leads to disruption of
Cγ2 spacing and signiﬁcantly impairs FcγR binding.15,16
The impact of Asn297 glycosylation upon Fc structure is not
limited to inﬂuencing Cγ2 spacing. IgG Fc glycosylation also
stabilizes the protein through an approximately 500 Å2 glycan−
protein interface along the surface of the Cγ2 domain.11,13,17
These glycan−protein contacts are believed to limit both the
processing by Golgi-resident glycosyltransferases and the
conformational freedom of the glycan.18 This model is
supported by an NMR study, which proposes that Fc glycans
exist in an equilibrium with an approximately equal proportion
of a “free” state, with highly mobile glycans, and a less mobile
“bound” state, observable by X-ray crystallography, with
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ordered protein−glycan interactions less accessible to enzy-
matic processing.19
The composition of IgG Fc glycans is largely directed by the
protein.18,20 The glycosylation exhibits limited processing and
consists of a predominantly biantennary complex-type frame-
work with partial occupancy of galactose, core α1→6-linked
fucose, low levels of “bisecting” GlcNAc, and sialic acid.18 This
limited processing is in contrast to the highly sialylated
complex-type glycosylation typically observed on secreted
glycoproteins.18
The human FcγRs (FcγRI, FcγRIIa, FcγRIIb, and FcγRIIIa)
display binding properties dependent upon the presence and
composition of the Fc glycan.1 For example, afucosylated
antibody glycoforms, which may ﬁnd utility in anticancer
treatment, are inﬂammatory and exhibit enhanced ADCC due
to elevated binding to the activatory FcγRIIIa.21 In contrast,
anti-inﬂammatory IgG glycoforms display increased levels of
terminal sialylation and are under investigation for enhanced
intravenous immunoglobulin therapy.22
Biosynthetic Fc precursors have also been investigated for
therapeutic applications due to their altered FcγR-dependent
eﬀector functions.9,23−26 Monoclonal antibodies found in the
early steps of carbohydrate maturation including oligomannose-
or afucosylated hybrid-type glycans, for example, display
increased aﬃnity for FcγRIIIa and enhanced ADCC function-
ality,24,26 albeit with potentially elevated serum clearance.27,28
Here, we have generated and characterized a panel of such
glycoform intermediates and present the crystal structure of the
key precursor bearing hybrid-type glycosylation. In the context
of the biosynthetic pathway of N-linked carbohydrates, this
glycoform represents the intermediate formed between the
immature oligomannose and the native, complex-type states.29
This Fc glycoform, generated by recombinant mammalian
protein expression in the presence of the Golgi α-mannosidase
II inhibitor, swainsonine,30,31 was crystallized and subjected to
X-ray crystallographic analysis to 2.4 Å resolution. Examination
of this structure reveals a novel interaction between
carbohydrate and protein components. Together with thermo-
stability analyses, the structure provides a model for the
conformational transitions that IgG Fc undergoes upon
glycoprotein maturation and provides a template for the
structure-guided engineering of therapeutic antibodies.
■ RESULTS AND DISCUSSION
Expression and Puriﬁcation of IgG Fc Glycoforms. A
panel of IgG1 Fc glycoforms, corresponding to key stages of the
Figure 1. The N-linked glycosylation processing pathway (left) and MALDI-TOF MS analysis of associated IgG1 Fc glycoforms (right). Following
protein folding and hydrolysis of the glucose cap, glycoforms were isolated by stalling the pathway at sequential stages of biogenesis. (A) The
Man9GlcNAc2 glycoform resulted from α-mannosidase (MI) inhibition with kifunensine. (B) The Man5GlcNAc2 glycoform resulted from expression
in a GlcNAc transferase (GnT) I-deﬁcient cell line. (C) Hybrid-type glycosylation resulted from expression in the presence of the Golgi α-
mannosidase II (GMII) inhibitor, swainsonine. (D) Complex-type glycosylation resulted from activity of Golgi-resident glycosyltransferases. Ions are
[M + Na]+. The sialylated glycan is also present as a sodium salt. The following symbols were used to represent glycans33 and are shown as a key in
panel D: yellow ⧫, galactose; blue ■, GlcNAc; green ●, Man; red ⧫ with black dot, fucose; pink ★, sialic acid. Linkage positions are shown by the
angle of the lines linking the sugar residues (vertical line, 2-link; forward slash, 3-link; horizontal line, 4-link; back slash, 6-link). Anomericity is
indicated by unbroken lines for β-bonds and broken lines for α-bonds.
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mammalian N-linked biosynthesis after calnexin/calreticulin-
mediated protein folding,29,32 was generated using either a
lectin-resistant cell line deﬁcient in glycosyltransferase activity
or by the use of glycosidase inhibitors (Figure 1).
We isolated IgG1 Fc bearing Man9GlcNAc2, Man5GlcNAc2,
hybrid-, and complex-type glycan structures. These glycoforms
are generally representative of the carbohydrates appearing in
the ER, and the early, medial, and late Golgi apparatus,
respectively.29,34
Glycan Analysis. The N-linked glycosylation of each Fc
glycoform was assessed by positive ion matrix-assisted laser
desorption/ionization (MALDI) time-of-ﬂight (TOF) mass
spectrometry (MS) of enzymatically released glycans (Figure
1). Expression of Fc in the presence of the ER and Golgi α1→
2-mannosidase inhibitor, kifunensine, resulted in a largely
homogeneous Man9GlcNAc2 glycan (m/z = 1905.6; Figure 1A)
with limited processing to the Man8GlcNAc2 derivative (m/z =
1743.6; Figure 1A). Expression of the Fc region in GnT I-
deﬁcient human embryonic kidney (HEK) 293S cells35 resulted
in a similarly homogeneous spectrum dominated by
Man5GlcNAc2 glycans (m/z = 1257.4; Figure 1B).
The next glycoform in the N-linked biosynthetic pathway,
the hybrid-type glycan, was isolated using the Golgi α-
mannosidase II inhibitor, swainsonine. Swainosine prevents
hydrolysis of the ManA and ManB saccharides of the “6-arm”
of the trimannosyl core.30,31 However, this inhibition does not
impede the addition of a GlcNAc residue to the “3-arm” Man4
by GnT I or subsequent structural elaborations.36 Consistent
with this mode of action, MALDI-TOF MS analysis of the N-
linked glycans of IgG1 Fc expressed with 10 μM swainsonine
revealed an heterogeneous spectrum of putative hybrid-type
glycans indicating variable terminal β1→4-linked galactose,
“bisecting” β1→4-linked GlcNAc, and a population of sialylated
hybrid-type glycans (m/z = 2081.7; Figure 1C). Finally, Fc
bearing complex-type glycans were generated using HEK 293T
cells with no inhibitors present. MALDI-TOF MS analysis
revealed biantennary complex-type glycans with variable
terminal galactose (Figure 1D). This spectrum is consistent
with previous observations that Fc glycosylation is highly
protein-directed20 and substantially less processed than other
glycoproteins similarly expressed using the pHLSec expression
vector in HEK 293T cells.37,38
Levels of both galactose and sialic acid in the hybrid-type
spectrum were higher than those observed for the complex-type
glycoforms. As sialic acid can alter the ionization eﬃciency of
glycans in mass spectrometry,39 we also subjected the hybrid
and complex-type glycans to electrospray ionization (ESI) mass
spectrometry (Figure 2). No sialylated structures were detected
by ESI−MS of the glycans released from the Fc glycoform
bearing complex-type glycans (Figure 2B). In contrast, the
spectrum of glycans deriving from Fc expressed in the presence
of swainsonine contained a prominent peak at m/z 2035.7
corresponding to a sialylated core-fucosylated hybrid-type
glycan (Figure 2A).
Isomeric assignments of the hybrid-type structures were
determined by negative-ion ESI MS/MS of the enzymatically
released glycans. The fragmentation spectra of the most
abundant species are presented in Figure 3. The m/z values
of the “D-type ions”, as deﬁned by Harvey,40 are a signature of
the 6-arm. These D-type ions are annotated in the spectra and
are formed by the formal loss of the 3-arm and the fucosylated
di-N-acetylchitobiose core. Similarly, the D′-type ions, formed
by cleavage of the 6-arm, reveal the cluster of mannose residues
on the 6-arm. Bisecting GlcNAc residues are revealed by an
abundant [D − 221]− ion at m/z 629 and the virtual absence of
a D-type ion41 (Figure 3B). The absence of an ion at m/z 306
shows that the sialic acid residue is α2→3-linked (Figure
3A).42,43 This linkage contrasts α2→6-linked sialic acid
observed in serum-derived antibodies.44
To assess the level of sialic acid in the hybrid-type glycans,
we expressed an intact IgG1 antibody hybrid-type glycoform
and subjected the ﬂuorescently derivatized glycans to normal-
phase HPLC. This analysis revealed that 20% of these
swainsonine-induced hybrid-type glycans were sialylated
(Figure 4A). Consistent with our MALDI−MS and ESI−MS
data of IgG1 Fc glycans, no sialylated structures were observed
in IgG produced in the absence of swainsonine (Figure 4B).
Swainsonine is not known to aﬀect galactosyltransferase or
sialyltransferase activity, as conﬁrmed by the similar glycan
proﬁles of the same glycoproteins expressed in HEK 293T cells
Figure 2. Negative ion electrospray mass spectra of recombinant IgG1 Fc N-linked glycans following expression in the (A) presence and (B) absence
of the Golgi α-mannosidase II inhibitor, swainsonine. Neutral glycan ions are [M + H2PO4]
−, sialylated glycans are [M − H]−. Symbols for the
structures are as described in Figure 1. Isomeric assignments were determined by ESI−MS/MS (Figure 3). The presence of a minor population of
Man4-based hybrids was detected in the fragmentation spectra by very low abundance
1,3A3 ions at m/z 424 (Figure 3B,D).
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Figure 3. Negative ion fragmentation spectra of the major N-linked glycans from the hybrid-type gycoform of IgG1 Fc. Neutral glycan ions are [M +
H2PO4]
−, while the sialylated glycan forms a [M − H]− ion. (A) Sialylated, fucosylated hybrid glycan (Man5Gal1GlcNAc3Fuc1NeuNAc1), m/z
2035.7. (B) Bisected, fucosylated hybrid glycan (Man5GlcNAc4Fuc1), m/z 1883.6. (C) Fucosylated hybrid glycan (Man5Gal1GlcNAc3Fuc1), m/z
1842.6. (D) Agalactosylated, fucosylated hybrid glycan (Man5GlcNAc3Fuc1), m/z 1680.5. The nomenclature describing fragmentation ions follows
that of Domon and Costello45 and is distinct from the carbohydrate residue labels (Figure 1).
Figure 4. HPLC analysis of ﬂuorescently labeled N-linked glycans from recombinant IgG1expressed in HEK 293T cells in (A) the presence and (B)
the absence of the GnT I inhibitor, swainsonine. The lower panels show the spectra of glycans following digestion with Arthrobacter ureafaciens
sialidase. Symbols for the structures are as described in Figure 1.
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in the presence of swainsonine and in HEK 293T Lec36 cells
that are devoid of Golgi α-mannosidase II activity.38 Similarly,
there was no evidence of increased terminal processing upon
disruption of Golgi α-mannosidase II activity as compared to
glycoproteins expressed in HEK 293T cells.38 Therefore, the
increased abundance of galactose and sialic acid residues in the
3-arm of the hybrid-type glycoform, as compared to the
complex glycoform, may be indicative of increased steric
accessibility of the Fc glycans to processing enzymes.
Thermodynamic Stability of Fc Glycoforms. One
explanation for the increased 3-arm processing of the hybrid-
type glycoform as compared to that of the complex-type glycan
is that the accessibility of the glycans is inﬂuenced by
composition and structure of the glycan−protein interface.
Because of the highly processed composition of the hybrid-type
glycoform, we hypothesized it would exhibit distinct glycan−
protein packing interactions with altered stability. We assessed
our panel of Fc glycoforms by diﬀerential scanning ﬂourimetry
(Figure 5).
This analysis revealed that relative to the melting temper-
ature (Tm) of the complex-type glycoform, the other glyco-
forms exhibited reduced Tm values: Man9GlcNAc2 (Tm = −2.8
± 0.7 °C), hybrid-type glycoforms (Tm = −4.0 ± 0.7 °C), and
endoglycosylated-treated Fc (−5.2 ± 1.0 °C). Therefore, in
addition to reducing glycan accessibility to glycosyltransferases,
the enzymatic action of Golgi α-mannosidase II, to produce
complex-type glycans, is permissive for the biosynthesis of a
more thermally stabilized Fc structure. We sought to investigate
the structural basis for this observation by X-ray crystallog-
raphy.
Structural Characterization of the Hybrid-Type Fc
Glycoform. Crystallographic structures of IgG Fc have been
reported for a number of glycoforms ranging from
oligomannose Man9GlcNAc2, to homogeneous complex-type,
and endoglycosidase-deactivated and aglycosylated
states.11,15,37,46 However, no crystallographic information is
available for the hybrid-type Fc glycoform that represents the
biosynthetic transition point between oligomannose and
complex-type glycosylation states. We determined the crystal
structure of this key intermediate (Table 1).
The hybrid-type glycoform crystallized in the primitive
orthorhombic spacegroup, P212121, with one homodimer in the
asymmetric unit. The Cγ3 protomers were very similar in
structure (0.3 Å root-mean-square deviation over 103
equivalent Cα residues) and exhibited noncrystallographic 2-
fold rotational symmetry. However, the orientations of the Cγ2
protomers were arranged such that they introduced asymmetry
to the homodimer, as has been frequently observed47,48 (Figure
6A,B). The protein and carbohydrate components of the Cγ2
domain of one chain (referred to here as chain A) were largely
ordered, while those from the other (chain B) exhibited higher
B-values where some Cγ3-distal loop regions and associated
glycan residues were disordered and not clearly visible in the
electron density (Figure 6A).
The diﬀerent conﬁgurations of the Cγ2 domains may arise
due to diﬀerences in stabilizing crystallographic packing
interactions. This hypothesis is supported by analysis of the
crystalline assembly.10 This analysis reveals that the Cγ2
domain of the more ordered chain A exhibits 37% more buried
surface area with symmetry-related molecules than does the
corresponding domain in chain B.
Biosynthetic Conformational Transitions. Overall Con-
formation. In chain A of our hybrid-type glycoform, we
observe electron density for eight saccharide residues,
corresponding to the entirety of the fucosylated oligomannose
component of the hybrid-type glycan (Figure 6B). No electron
density was observed for the processed 3-arm beyond Man4.
The 3-arm is entirely solvent exposed with the nearest
Figure 5. Thermodynamic stability of IgG1 Fc glycoforms. Single
thermostability measurements of oligomannose (Man9GlcNAc2),
hybrid, and complex-type glycoforms are shown. Measurements
were performed in triplicate.
Table 1. Crystallographic Data and Reﬁnement Statistics
Data Collection
beamline BM-14
resolution range (Å) 50.0−2.36 (2.44−2.36)a
space group P212121
cell dimensions
a, b, c (Å) 49.0, 72.9, 140.8
α, β, γ (deg) 90.0, 90.0, 90.0
wavelength (Å) 0.953
unique reﬂections 21 447 (2094)
completeness (%) 99.3 (98.7)
Rmerge (%)
b 9.9 (65.3)
I/σI 16.5 (2.4)
avg redundancy 4.8 (4.5)
Reﬁnement
resolution range (Å) 40.0−2.36 (2.42−2.36)
no. of reﬂections 21 379 (1459)
Rwork (%)
c 21.5
Rfree (%)
d 26.6
rmsde
bonds (Å) 0.006
angles (deg) 1.2
molecules per asuf 1
atoms per asu (protein/carbohydrate/water) 3183/93/218
average B-factors (Å2)
(protein/carbohydrate/water)
43.2/84.7/36.8
model quality (Ramachandran plot)g
most favored region (%) 99.5
allowed region 0.5
aNumbers in parentheses refer to the relevant outer resolution shell.
bRmerge = ∑hkl∑i|I(hkl;i) − ⟨I(hkl)⟩|/∑hkl∑iI(hkl;i), where I(hkl;i) is
the intensity of an individual measurement and ⟨I(hkl)⟩ is the average
intensity from multiple observations. cRwork = ∑hkl||Fobs| − k|Fcalc||/
∑hkl|Fobs|. dRfree is calculated as for Rwork, but using only 5% of the data,
which were sequestered prior to reﬁnement. ermsd: root-mean-square
deviation from ideal geometry. fasu: asymmetric unit. gRamachandran
plots were calculated with Molprobity.49
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component of a symmetry-related molecule located 9 Å away.
While we cannot formally exclude the possibility of selective
crystallization of a subset of hybrid-type glycoforms, this
distance, and the large accessible volume surrounding the 3-
arm, provides no evidence for such a phenomenon.
From the observation that the conformations of complex-
type glycans are not inﬂuenced by the presence of fucose,46 we
suggest that the structure of the Man5GlcNAc2 component of
the hybrid-type glycan reported herein is likely to resemble the
Man5GlcNAc2 glycoform that occurs in the preceding stage of
the pathway (Figure 1). This assertion, combined with analysis
of the previously reported Man9GlcNAc2 Fc structure
47 and the
series of complex-type structures by Krapp et al.,11 now enables
us to propose a model of glycan maturation during antibody
biogenesis.
The folded Man9GlcNAc2 glycoform is generated following
the hydrolysis of the glucose cap and consequent release from
the calnexin/calreticulin folding check-point.32 All available
structures of Fc glycoforms show a conserved mode of
interaction of the saccharide residues proximal to the protein
attachment site. The Manβ1→4GlcNAcβ1→4GlcNAc core and
the observable 3-arm residues exhibit highly similar con-
formations and glycan−protein packing interactions. In
contrast, the 6-arm residues exhibit divergent conformations
reﬂecting the diﬀerent chemical compositions and/or surround-
ing environments of the glycan residues (Figure 7).
Transition from Man9GlcNAc2 to Man5GlcNAc2. The
structural rearrangements that occur within the oligosaccharide
when carbohydrates are modiﬁed are illustrated by the
hydrolysis of terminal α1→2 mannose residues of the
Man9GlcNAc2 glycoform. The ManD3 residue in the
Man9GlcNAc2 structure anchors the oligosaccharide chain to
the protein surface at the junction of the Cγ2 and Cγ3 domains
(Figure 7A). As the solvent accessible ManD1 and ManD2
residues are disordered in the crystal structure,47 hydrolysis of
ManD3 is likely to induce the observed rearrangement of the 6-
arm and cause the 6 Å shift of ManB (Figure 7A,B). This
cleavage also results in the associated relaxation of the
Man4′α1→6Man3 linkage (from φ = 69°, ψ = −178°, ω =
62° to φ = 77°, ψ = 101°, ω = 30°; Figure 7A,B). Despite this
movement, the Man4′ residue in the Man5GlcNAc2 glycoform
is orientated in a direction opposite to that of complex-type
structures (Figure 7C). This orientation is maintained by the
presence of ManA and ManB residues of the 6-arm that
sterically prevent further rotation of the Man4′α1→6Man3
linkage (Figure 7B).
Transition from Man5GlcNAc2 to Hybrid-Type. The action
of GnT I on Man5GlcNAc2 catalyzes the formation of hybrid-
type glycans and allows downstream carbohydrate processing
(Figure 1). GnT I transfers β1→2-linked GlcNAc to the Man4
residue of the 3-arm to form the GlcNAc5β1→2Man4 linkage
(Figure 7B,C). As for many structures of complex-type
glycoforms, we do not observe interpretable electron density
for the solvated and mobile residues on this arm. Additionally,
GnT I catalysis also renders the core GlcNAc residue
(GlcNAc1) of the hybrid-type glycan susceptible to α1→6-
fucosylation.36 We observe electron density for the fucose and
note the conformation closely resembles that of the complex-
type glycoform (Figure 7B,C). This supports our assertion that
Man5GlcNAc2 glycans are not aﬀected structurally by
fucosylation.
Formation of Complex-type Glycans. Golgi α-mannosidase
II hydrolyses the α1→3-linked ManA and α1→6-linked ManB
residues from the 6-arm and is dependent upon the prior
activity of GnT I (Figure 1). Elimination of these residues
relieves steric restraints around the 6-arm and allows the
reorientation of the Man4′α1→6Man3 linkage (from φ = 77°,
ψ = 101°, ω = 30° to φ = 62° ψ =171°, ω = −175°; Figure
7B,C), causing close alignment of the glycan to the protein
surface.
Following this rearrangement, GnT II catalyzes the transfer
of β1→2-linked GlcNAc to Man4′, allowing the formation of
hydrophobic stacking interactions between GlcNAc5′ and
Phe243 (Figure 7C). The formation of these canonical
glycan−protein interactions is consistent with the increased
stability17 (Figure 5 and Supporting Information Figure S1)
and decreased enzymatic processing of the mature complex-
type glycoform relative to the artiﬁcially trapped hybrid-type
glycoform (Figures 1, 2, and 4). Limited downstream
compositional heterogeneity of the complex-type glycoform
subsequently arises from the partial transfer of galactose to
terminal GlcNAc5 and GlcNAc5′ residues18 and leads to little
change with respect to carbohydrate conformation or thermal
stability.11,17
Evidence for the suppression of galactosylation and
sialylation by the interaction between GlcNAc5′ and Phe243
is provided by the analysis of IgG from a patient with a
homozygous mutation in the Mgat2 gene.50 Mgat2 encodes
GnT II that catalyzes the transfer of the 6-arm GlcNAc5′ to
Man4′. The IgG Fc glycans isolated from the patient lacked 6-
arm GlcNAc5′ but exhibited signiﬁcantly elevated 3-arm
Figure 6. Crystal structure of the hybrid-type glycoform of human
IgG1 Fc. (A) The Fc structure with the protein moiety shown as a gray
ribbon with the N-linked glycan of N297 shown as sticks.
Carbohydrate residues are colored and labeled as in Figure 1. A
maximum likelihood weighted 2Fo − Fc electron density map is plotted
around the glycan at 1σ. (B) Panel A rotated 70° with a close-up view
of the protein and carbohydrate components of the Cγ2 domain from
chain A of the hybrid Fc crystal structure. No electron density was
observed for the processed 3-arm beyond Man4. (C) Overlay of the
protein backbone of the hybrid (gray), oligomannose (cyan; PDB
accession code 2WAH), and complex-type (pink; PDB accession code
3AVE) glycoforms. (D) The overlay in panel C rotated 90° with a
dashed line corresponding to a 17 Å distance between equivalent
Ser298 Cα atoms in the hybrid- and complex-type glycoforms.
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processing as compared to wild-type structures with the
majority of glycans containing the NeuNAc7α2→6Gal6β1→
4GlcNAc5 motif.50 Together with our structural observations,
we suggest that the action of Golgi α-mannosidase II and GnT
II enhance the glycan−protein interface and limit glycosyl-
transferase accessibility to the 3-arm.
■ SUMMARY AND CONCLUSIONS
The use of glycosidase inhibitors and cell-lines with genetically
modiﬁed glycan processing enzymes oﬀers a powerful route to
the isolation of glycoproteins with deﬁned glycan struc-
tures.34,51 These methods oﬀer an attractive alternative to
direct chemical synthesis and can be readily combined with
chemoenzmatic methodologies.3,7,8,52,53
Analysis of isolated biosynthetic intermediates of IgG1 Fc
revealed distinct diﬀerences in the susceptibility of discrete
glycan states to glycosyltransferases. Speciﬁcally, we have
shown by mass spectrometry that the trapped hybrid-type
glycans are more readily accessible to galactosyl and
sialyltransferases than are complex-type structures. The
generation of hybrid-type glycoforms with increased Fc
sialylation is of note given the enhanced anti-inﬂammatory
functionality exhibited by sialylated Fc in, for example,
intravenous immunoglobulin therapy.22
The biosynthetic intermediates also exhibited reduced
stability, an important parameter in the development of
antibody therapeutics.54 Through our X-ray crystallographic
analysis, we correlate this stability to structural transitions that
occur during antibody biogenesis. We oﬀer a molecular-level
explanation for how stability arises from rearrangements of the
glycan−protein interface. We deduce that glycan-dependent
stabilization occurs during Golgi α-mannosidase II and GnT II
processing, which respectively cause the relaxation of the 6-arm
toward the protein surface and the formation of hydrophobic
glycan−protein interfaces.
Given the promising portfolio of eﬀector functions exhibited
by IgG bearing oligomannose and hybrid-type gly-
cans,15,24,25,27,28 knowledge of their three-dimensional structure
and deﬁned molecular transitions provides a template to
support structure-guided stabilization and optimization for the
clinic.
■ EXPERIMENTAL PROCEDURES
Protein Expression and Puriﬁcation. The Fc region of human
IgG1 (residues 120−329, GenBank accession no. J00228) was cloned
into the pHLSec vector55 and transiently expressed in HEK 293T cells
(ATCC number CRL-1573), GnT I-deﬁcient HEK 293S cells,35 and
in the presence of mannosidase inhibitors to isolate glycoforms of
distinct composition.34 Transfections were performed using 2 mg of
DNA per liter cell culture medium as previously described.55 Fc
bearing Man9GlcNAc2 and hybrid-type glycosylation were obtained by
expression in the presence of 20 and 10 μM of the inhibitors,
kifunensine34 and swainsonine,31 respectively (Toronto Research
Figure 7. Structural transitions of IgG1 Fc glycans between (A) oligomannose-type (PDB accession code 2WAH), (B) hybrid-type, and (C)
complex-type glycosylation (PDB accession code 3AVE), as observed by X-ray crystallography. The left-hand column displays the glycan packing
against the Cγ2 domain. The central column shows a view with the 6-arm in the foreground. The right-hand column is a close-up and shows the
conformational changes occurring within the 6-arm; an asterix indicates the location of the C6 carbon of the Man4′ residue. The protein surface is
colored gray, the F243 side-chain is colored pink, and the glycan is colored as in Figure 1 except in the close-up where the oxygen atoms of mannose
residues are shown in red.
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Chemicals, Canada). Inhibitors were added at the time of transfection,
and the supernatants were harvested after 5 days. IgG1 Fc
glycoproteins were puriﬁed at room temperature by immobilized
metal-aﬃnity chromatography (GE Healthcare, Bucks, UK) and size
exclusion chromatography using a Superdex 200 10/30 column
(Amersham, Bucks, UK), in a buﬀer containing 150 mM NaCl and 10
mM Tris pH 8.0. Yields were typically 20 mg of puriﬁed IgG1 Fc per
liter cell culture.
Plasmids encoding IgG1 b12 light and heavy chains were kindly
provided by Professor Dennis Burton (The Scripps Research Institute,
CA). The heavy and light chains were transiently cotransfected in
HEK 293T cells in the presence or absence of 10 μM swainsonine.31
IgG1 b12 was puriﬁed by incubation for 2 h with Protein A Sepharose
(GE Healthcare, UK) at room temperature. The beads were washed
with phosphate buﬀered saline (PBS) before elution using 0.1 M citric
acid pH 3.4 followed by neutralization and size exclusion
chromatography. Yields were typically 8 mg of puriﬁed IgG1 b12
per liter cell culture.
Thermodynamic Stability of IgG1 Fc Glycoforms. The thermal
stability of diﬀerent Fc glycoforms was assessed by diﬀerential
scanning ﬂuorimetry using a Stratagene RT PCR 305 instrument.
Thermally induced unfolding of puriﬁed Fc glycoforms was monitored,
in triplicate, by measuring Absorbance at 610 nm at 1.5 °C increments
in the presence of Sypro Orange (Invitrogen, Paisley, UK), a
ﬂuorescent stain sensitive to hydrophobic environments.56
Glycan Analysis. Oligosaccharides were released from target
glycoproteins with peptide-N-glycosidase F (New Englands Biolabs)
from Coomassie blue-stained NuPAGE gels.57 Excised bands were
washed ﬁve times alternatively with acetonitrile and deionized water,
and rehydrated with a 3000 units/mL of aqueous PNGase F solution.
After 12 h incubation at 37 °C, the enzymatically released N-linked
glycans were eluted with water. Samples were analyzed by MALDI-
TOF MS with a Shimadzu AXIMA TOF2 MALDI TOF/TOF mass
spectrometer (Kratos Analytical, Manchester, UK) ﬁtted with delayed
extraction and a nitrogen laser (337 nm). Samples were cleaned on a
Naﬁon 117 membrane (Aldrich), and then prepared for MALDI-MS
by adding 0.5 μL of an aqueous solution of the glycans to the matrix
solution (0.3 μL of a solution of 2,5-dihydroxybenzoic acid in
acetonitrile:water; 1:1, v:v) on the stainless steel target plate and
allowing it to dry at room temperature. The sample/matrix mixture
was then recrystallized from ethanol.
Negative ion ESI−MS was performed with a Waters Synapt G2
traveling wave ion mobility mass spectrometer (Waters MS-
Technologies, Manchester, UK).58 Samples were dissolved in a
solution of methanol:water (1:1, v:v) containing 0.5 M ammonium
phosphate and introduced into the instrument with Waters thin-wall
nanospray capillaries. The ESI capillary voltage was 1.2 kV, the cone
voltage was 20−180 V, and the ion source temperature was 120 °C.
The T-wave velocity and peak height voltages were 450 m/s and 40 V,
respectively. The T-wave mobility cell contained nitrogen and was
operated at a pressure of 0.55 mbar and was used to provide an
additional selection stage for the fragmentation experiments.
Fragmentation was performed after mobility separation in the transfer
cell with a 3 mass unit selection window and with argon as the
collision gas. The instrument was externally calibrated with sialylated
N-glycans released from bovine fetuin. Data acquisition and processing
were carried out using Waters Driftscope (version 2.1) software and
MassLynx (version 4.1).
Fluorescent labeling of glycans with 2-aminobenzoic acid (2-AA)
and subsequent HPLC analysis was performed as previously
described.59,60 Brieﬂy, a buﬀered glycan solution was mixed with 2-
AA and sodium cyanoborohydride. Labeling was achieved by
incubation for 1 h at 80 °C. Excess 2-AA was removed using a Spe-
ed Amide-2 column (Systematic Instruments, UK). HPLC was carried
out at room temperature in a 20 mM ammonium hydroxide solution
(pH 3.9) with a linear gradient of acetonitrile and water.
Exoglycosidase digestions were performed as previously described.60
Crystallization and Structure Determination. Crystals of IgG1
Fc bearing hybrid-type glycans were grown by sitting-drop vapor
diﬀusion using 100 nL of protein solution (11.4 mg mL−1) plus 100
nL of precipitant using the previously described semiautomated
robotics of the Oxford Protein Production Facility.61 Crystals of IgG
Fc bearing hybrid-type glycans grew at 20 °C in 20% w/v PEG 3350
pH 5.5 with 0.2 M sodium/potassium phosphate after 4 days. Crystals
were ﬂash frozen by immersion in a cryoprotectant containing 25%
ethylene glycol and transferred to a gaseous nitrogen stream at 100 K.
Data were collected at beamline BM14 at the European Radiation
Synchrotron Facility, Grenoble, France (Table 1). Diﬀraction data
were integrated and scaled using the programs DENZO and
SCALEPACK,62 and the structure was solved by molecular
replacement using the program Phaser63 with the protein chain from
a natively glycosylated IgG Fc46 (PDB accession code 3AVE) as a
search model. Five percent of reﬂections was randomly set aside to
calculate the Rfree. Generally, the hybrid Fc structure was reﬁned using
Refmac5 in the CCP4 suite64 and included iterative restrained
reﬁnement with translation libration screw parametrization and
incorporation of automatically generated local noncrystallographic
symmetry restraints.65,66 The molecular graphics program Coot was
used for manual rebuilding,67 and MolProbity was used to validate the
model.49 Data processing, reﬁnement, and structure validation
statistics are presented in Table 1.
Nomenclature. Throughout this work, we have adopted the
system of Vliegenhart et al.68 for labeling residues within
oligomannose- and biantennary-type oligosaccharides with the addi-
tional modiﬁcations of 7 and 7′ for sialic acid, 1′ for α1→6-linked core
fucose69 (Figure 1). These residue labels are in bold-face throughout
this Article. The symbolic representation of glycans follows that of
Harvey et al.33 with residues in both the schematic diagrams and the
molecular graphics following the color scheme of the Centre for
Functional Glycomics. Carbohydrate fragmentation ions are labeled
using the Domon and Costello nomenclature45 with an extension by
Harvey.70
Dihedral angles were deﬁned using the “x − 1” system for
crystallography: φ = O5−C1−O−C(x)′ and ψ = C1−O−C(x)′−C(x
− 1)′ for Manα1→2Man and Manα1→3Man, where x = 2 or 3,
respectively; φ = O5−C1−O−C6′, ψ = C1−O−C6′−C5′, and ω =
O−C6′−C5′−C4′ for Manα1→6Man linkages.71
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(8) Mraźek, H.; Weignerova,́ L.; Bojarova,́ P.; Novaḱ, P.; Vaneǩ, O.;
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